The award acknowledges Metropolis Healthcare's integrated quality intelligence framework, which combines scientific rigor, data-driven governance, advanced analytics, standardized laboratory practices, and continuous quality monitoring. The framework ensures consistency across every stage of the diagnostic process, from sample collection and transportation to testing and report delivery.
Metropolis currently delivers 99.99 percent report accuracy across 3,512 diagnostic tests and maintains 100 percent compliance with ISO 15189:2022 standards across its accredited laboratories. The company continuously monitors critical quality parameters through advanced analytics platforms. Its quality infrastructure is reinforced by 582 NABL-accredited sample collection facilities and a network of more than 275 authorized signatories responsible for scientific oversight, reporting governance, and verification of every new test, method, and platform before implementation.
Over the years, Metropolis has invested significantly in building one of India's most comprehensive laboratory excellence ecosystems. Its governance framework extends across more than 210 laboratories and thousands of patient touchpoints, supported by NABL and CAP accreditations, standardized operating procedures, structured audit systems, real-time monitoring, and analytics-driven quality control processes.
One of the company's major innovations is the Quality Score Index, a first-of-its-kind scientific performance framework designed to establish measurable and uniform benchmarks across laboratories. The framework assesses performance through multiple scientific and operational parameters, including audit outcomes, external quality assurance performance, compliance indicators, complaint resolution timelines, and academic engagement metrics. The initiative has played a significant role in driving continuous quality improvement throughout the network.
Building upon this foundation, Metropolis has introduced several advanced scientific and digital initiatives, including an AI-assisted Directory of Services and Tests and Next Best Action clinical intelligence tools. These systems support evidence-based diagnostic interpretation and enhance clinical decision-making. The framework is further strengthened through annual audits aligned with ISO 15189, CLSI, and CAP guidelines, along with Internal Quality Control analytics, digital audit management systems, and real-time intelligence dashboards. These measures enable proactive identification of quality gaps, faster corrective actions, and continuous operational improvement, ultimately enhancing diagnostic confidence and consistency for both patients and healthcare providers.
Commenting on the achievement, Surendran Chemmenkotil, Managing Director of Metropolis Healthcare Limited, stated that quality in diagnostics directly influences clinical decision-making and patient outcomes, making it one of the most critical responsibilities in healthcare. He said the recognition validates the company's long-standing commitment to building a deeply integrated and standardized quality ecosystem across its network. He added that as the company expands its presence, its focus remains on ensuring that every patient receives the same high standards of diagnostic accuracy, reliability, and scientific excellence regardless of location. He emphasized that initiatives such as the Quality Score Index and the Pre-Analytical Compliance framework demonstrate the organization's commitment to making excellence measurable, transparent, and continuously improvable.
Dr. Kirti Chadha, Chief Scientific and Innovation Officer of Metropolis Healthcare Limited, said that quality is not viewed as a checkpoint but as an evolving scientific discipline embedded across every stage of laboratory operations. She noted that the company's integrated quality intelligence framework combines accreditation standards, structured governance, advanced analytics, internal quality controls, External Quality Assurance Scheme monitoring, and continuous professional development of laboratory personnel. According to her, the recognition reflects the collective dedication of the company's scientific and operational teams toward delivering consistent, reliable, and clinically meaningful diagnostic services.
Metropolis Healthcare's quality ecosystem is further supported by 100 percent participation in External Quality Assurance Programmes and specialist-led medical governance. Backed by more than four decades of diagnostic expertise, the organization continues to focus on advancing diagnostic excellence, strengthening patient trust, and improving healthcare outcomes through scientific innovation and operational discipline.
Established in 1981, Metropolis Healthcare Limited has emerged as a leading diagnostic services provider in India and Africa. Under the leadership of Ameera Shah, the company operates across 28 states, seven Union Territories, and more than 750 towns in India. Its extensive network includes over 219 laboratories, more than 5,000 patient service centers, and over 10,000 healthcare touchpoints. Every year, the company serves millions of individuals by delivering actionable health insights that support improved clinical outcomes.
Metropolis offers more than 4,100 tests and diagnostic profiles, including advanced investigations for cancer, neurological disorders, infectious diseases, and genetic abnormalities. Its commitment to quality is reflected in a CAP proficiency score exceeding 99 percent over the past decade, placing it among the top one percent of laboratories globally for quality assurance. The company continues to build its reputation on technological excellence, patient-centric care, and reliable diagnostic reporting, reinforcing its position as one of the most trusted names in the healthcare diagnostics sector.
About The Author
Comment List